[go: up one dir, main page]

BRPI0517989A - processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, e, composto ou um sal do mesmo - Google Patents

processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, e, composto ou um sal do mesmo

Info

Publication number
BRPI0517989A
BRPI0517989A BRPI0517989-0A BRPI0517989A BRPI0517989A BR PI0517989 A BRPI0517989 A BR PI0517989A BR PI0517989 A BRPI0517989 A BR PI0517989A BR PI0517989 A BRPI0517989 A BR PI0517989A
Authority
BR
Brazil
Prior art keywords
compound
salt
pharmaceutically acceptable
preparing
acceptable salt
Prior art date
Application number
BRPI0517989-0A
Other languages
English (en)
Inventor
James Michael Mcnamara
Louis Matty
Jonathan D Rosen
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0517989A publication Critical patent/BRPI0517989A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

PROCESSO PARA PREPARAR UM COMPOSTO OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, E, COMPOSTO OU UM SAL DO MESMO. A presente invenção refere-se a um processo para a preparação do composto ácido {3 - ¢2(R)-Li R)- 1- ¢3,5-bis (trifluorometil) fenil!etóxi!-3 (5)-(4-fluorofenil)morfolin-4-il ¢metil! -5 -oxo-4,5 -diidro- ¢1,2,4! -triazol- 1- il}fosfónico e sais farmaceuticamente aceitáveis do mesmo. Este composto é útil como um antagonista do receptor da substância P (neurocinina- 1). Em particular, o composto é útil, por exemplo, no tratamento de êmese e doenças inflamatórias.
BRPI0517989-0A 2004-11-05 2005-11-03 processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, e, composto ou um sal do mesmo BRPI0517989A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62520904P 2004-11-05 2004-11-05
PCT/US2005/039946 WO2006060110A2 (en) 2004-11-05 2005-11-03 Process for preparing {3-[2(r)-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)morpholin-4-yl]methyl]-5-oxo-4,5-dihydro-[1,2,4]-triazol-1-yl}phosphonic acid

Publications (1)

Publication Number Publication Date
BRPI0517989A true BRPI0517989A (pt) 2008-10-21

Family

ID=36263958

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517989-0A BRPI0517989A (pt) 2004-11-05 2005-11-03 processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, e, composto ou um sal do mesmo

Country Status (12)

Country Link
US (2) US7807829B2 (pt)
EP (1) EP1809379B1 (pt)
JP (1) JP4917541B2 (pt)
CN (2) CN103130834A (pt)
AR (1) AR051475A1 (pt)
AT (1) ATE529162T1 (pt)
AU (1) AU2005310240B9 (pt)
BR (1) BRPI0517989A (pt)
CA (1) CA2586114A1 (pt)
ES (1) ES2373451T3 (pt)
TW (1) TWI358413B (pt)
WO (1) WO2006060110A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2715781C (en) * 2008-02-26 2016-06-28 Sandoz Ag Preparation of morpholine derivatives
EP2303901B2 (en) 2008-07-17 2018-05-09 Glenmark Pharmaceuticals Limited Fosaprepitant dimeglumine intermediate, neutral fosaprepitant, and amorphous fosaprepitant dimeglumine and processes for their preparations
WO2011045817A2 (en) 2009-10-15 2011-04-21 Sandoz Private Limited Process for the preparation of fosaprepitant, intermediate and pharmaceutical acceptable salt thereof
CN102166199B (zh) * 2011-04-02 2012-11-07 武汉希熙生物科技有限公司 一种注射用福沙吡坦二甲葡胺冻干制剂的制备方法
WO2012146692A1 (en) 2011-04-29 2012-11-01 Sandoz Ag Novel intermediates for the preparation of highly pure aprepitant or fosaprepitant
CN102850398B (zh) * 2011-06-27 2015-06-10 上海医药工业研究院 制备福沙匹坦的方法
CN102977142B (zh) * 2011-09-02 2017-03-29 江苏豪森药业集团有限公司 福沙匹坦二甲葡胺的制备方法
CN103030668B (zh) * 2011-10-09 2016-06-15 江苏豪森药业集团有限公司 一种制备福沙匹坦二甲葡胺的方法
CN103183708A (zh) * 2011-12-31 2013-07-03 扬子江药业集团上海海尼药业有限公司 福沙吡坦二甲葡胺的制备方法
CN102558232B (zh) * 2011-12-31 2015-04-08 江苏奥赛康药业股份有限公司 一种福沙吡坦二甲葡胺的制备方法
WO2013168176A2 (en) * 2012-03-30 2013-11-14 Glenmark Generics Limited Process for preparation of fosaprepitant and salt thereof
CN102675369B (zh) * 2012-05-16 2017-07-11 北京华众思康医药技术有限公司 一种制备[3‑[(2r)‑[(1r)‑1‑[3，5‑二(三氟甲基)苯基]乙氧基]‑3(s)‑(4‑氟苯基)吗啉‑4‑基]甲基]‑5‑氧代‑4，5‑二氢‑[1，2，4]‑三唑‑1‑基]膦酸一苄酯的新方法
CN102838634B (zh) * 2012-09-28 2015-05-13 江苏奥赛康药业股份有限公司 一种降低化合物中钯残留的方法及应用这种方法的高纯度福沙匹坦二甲葡胺的制备方法
CN102850399B (zh) * 2012-09-28 2015-03-04 江苏奥赛康药业股份有限公司 一种福沙匹坦二甲葡胺的精制方法
CN103159797A (zh) * 2013-03-29 2013-06-19 山东罗欣药业股份有限公司 福沙吡坦二甲葡胺晶型化合物
CN103204878A (zh) * 2013-03-29 2013-07-17 山东罗欣药业股份有限公司 一种福沙吡坦二甲葡胺的合成方法
CN104098604B (zh) * 2013-04-10 2016-12-28 山东省生物药物研究院 一种制备福沙匹坦二甲葡胺的方法
CN105254668B (zh) * 2013-05-14 2017-10-10 北京百川汇德医药技术开发有限公司 一种福沙匹坦及其可药用盐的制备新方法
WO2015083033A1 (en) * 2013-12-02 2015-06-11 Piramal Enterprises Limited An improved process for the preparation of fosaprepitant having improved purity
US9850267B2 (en) 2015-06-03 2017-12-26 Navinta, Llc Crystalline fosaprepitant dicyclohexylamine salt and its preparation
SG11201803645PA (en) * 2015-11-19 2018-06-28 Biohaven Pharm Holding Co Ltd Amine prodrugs of pharmaceutical compounds
EP3383829B1 (en) 2015-12-01 2020-10-21 Piramal Enterprises Limited A process for preparation of fosaprepitant dimeglumine and an intermediate thereof
CN108948080B (zh) * 2017-05-22 2022-03-04 齐鲁制药有限公司 一种福沙匹坦药用盐的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
EP1309605A1 (en) * 2000-08-18 2003-05-14 The Board Of Trustees Of The University Of Illinois Prodrugs of betulinic acid derivatives for the treatment of cancer and hiv

Also Published As

Publication number Publication date
US7915407B2 (en) 2011-03-29
JP2008518970A (ja) 2008-06-05
AU2005310240B9 (en) 2011-10-13
CA2586114A1 (en) 2006-06-08
TWI358413B (en) 2012-02-21
AU2005310240A1 (en) 2006-06-08
AR051475A1 (es) 2007-01-17
ATE529162T1 (de) 2011-11-15
CN103130834A (zh) 2013-06-05
CN101056672A (zh) 2007-10-17
WO2006060110A2 (en) 2006-06-08
TW200631959A (en) 2006-09-16
US20070265442A1 (en) 2007-11-15
WO2006060110A3 (en) 2006-08-17
EP1809379B1 (en) 2011-10-19
US7807829B2 (en) 2010-10-05
EP1809379A2 (en) 2007-07-25
AU2005310240B2 (en) 2011-06-09
JP4917541B2 (ja) 2012-04-18
US20100324287A1 (en) 2010-12-23
ES2373451T3 (es) 2012-02-03

Similar Documents

Publication Publication Date Title
BRPI0517989A (pt) processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, e, composto ou um sal do mesmo
ATE555105T1 (de) Heterocyclische fxr-bindende verbindungen
BRPI0214786B8 (pt) composições nanoparticulada, e farmacêutica
ATE515505T1 (de) Heterocyclische fxr-bindende verbindungen
BRPI0518360A2 (pt) composto e sais farmaceuticamente aceitÁveis do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar um composto ou um sal farmaceuticamente aceitÁvel do mesmo
US20100234349A1 (en) Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
PE20080895A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
JP2011502958A5 (pt)
MX351463B (es) Formas cristalinas de 1-(5'-(5-(3,5-dicloro-4-fluorofenil)-5-(trif luorometil)-4,5-dihidroisoxazol-3-il)-3'h-espiro[azetidin-3,1'-is obenzofuran]-1-il)-2-(metilsulfonil)etanona.
NZ592792A (en) Heterocyclically substituted aryl compounds as hif inhibitors
EA201070164A1 (ru) Твердый препарат, включающий алоглиптин и гидрохлорид метформина
EA201001696A1 (ru) СОЕДИНЕНИЯ ХИНУКЛИДИНА В КАЧЕСТВЕ ЛИГАНДОВ НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА α7
BRPI0512058A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
BR122019016794B8 (pt) derivados de arilamida substituídos por tetrazol, composição farmacêutica que os compreende e seu uso no tratamento de uma condição inflamatória e/ou autoimune
SI2419104T1 (en) Combinations of 5-HT4 receptor agonists and acetylcholinesterase inhibitors for the treatment of cognitive disorders
BRPI0607600A2 (pt) derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina
BR0309277A (pt) Processo para preparação de um composto
BRPI0413584A (pt) composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de doenças e para tratamento de um distúrbio no sistema nervoso central
EA201071352A1 (ru) Трициклические азотсодержащие соединения и их применение в качестве бактерицидных средств
CN106687626A (zh) 作为d‑氨基酸氧化酶抑制剂的已知化合物的用途
MY147474A (en) 1-[(4-[benzoyl(methyl)amino]-3-(phenyl)butyl]azetidine derivatives for the treatment of gastrointestinal disorders 1
EA019037B1 (ru) 5-[5-[2-[3,5-бис(трифторметил)фенил-2-метилпропаноилметиламино]-4-(4-фтор-2-метилфенил)]-2-пиридинил]-2-алкилпролинамиды в качестве антагонистов рецептора nk1
BRPI0610907A2 (pt) composto ou precursores hidrolisÁveis in vivo ou sal farmaceuticamente aceitÁvel do mesmo, mÉtodos de tratamento ou profilaxia de uma doenÇa ou condiÇço na qual a modulaÇço do receptor de mch1 É benÉfica e de tratamento ou profilaxia de doenÇas, composiÇço farmacÊutica, e, uso de um composto
RU2372348C2 (ru) Производные индолилмалеимида в качестве ингибиторов ркс

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

Free format text: NOME ALTERADO DE: MERCK AND CO., INC.

B25A Requested transfer of rights approved

Owner name: SCHERING CORPORATION, (US)

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/675 (2006.01), A61P 29/00 (2006.01), C07F

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]